Evidence map›Paper›PMID 38318506›Full record

ArticleFrontiers in immunology2023

Canine diabetes mellitus demonstrates multiple markers of chronic inflammation including Th40 cell increases and elevated systemic-immune inflammation index, consistent with autoimmune dysregulation.

Gisela Vaitaitis, Tracy Webb, Craig Webb, Christina Sharkey, Steve Sharkey, Dan Waid, David H Wagner

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Reference Intervals for Hematological Inflammatory Ratios in Healthy Dogs.Animals : an open access journal from MDPI · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Gisela VaitaitisDepartment of Medicine, The University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Tracy WebbDepartment of Clinical Sciences, The Colorado State University Veterinary Teaching Hospital, Fort Collins, CO, United States.
Craig WebbDepartment of Clinical Sciences, The Colorado State University Veterinary Teaching Hospital, Fort Collins, CO, United States.
Christina SharkeyDepartment of Clinical Sciences, Montclaire Animal Clinic, Denver, CO, United States.
Steve SharkeyDepartment of Clinical Sciences, Montclaire Animal Clinic, Denver, CO, United States.
Dan WaidOp-T, LLC, Fitzsimmons Innovation Bioscience, Aurora, CO, United States.
David H WagnerDepartment of Medicine, The University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Colorado State University · USUniversity of Colorado Anschutz Medical Campus · US

Funding

Discovering the Mechanism of Action of a peptide drug, OPT101, that targets CD40 mediated inflammation in type 1 diabetesR01DK131196 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI WAGNER, DAVID H. · 2022 to 2025
$1.7M
NIDDK NIH HHS R01 DK131196
6 · The paper itself

Abstract

Introduction: Canine diabetes mellitus (CDM) is a relatively common endocrine disease in dogs. Many CDM clinical features resemble human type 1 diabetes mellitus (T1DM), but lack of autoimmune biomarkers makes calling the disease autoimmune controversial. Autoimmune biomarkers linking CDM and T1DM would create an alternative model for drug development impacting both human and canine disease. Methods: We examined peripheral blood of diagnosed CDM dog patients comparing it to healthy control (HC) dogs. Dogs were recruited to a study at the Colorado State University Veterinary Teaching Hospital and blood samples collected for blood chemistry panels, complete blood counts (CBC), and immunologic analysis. Markers of disease progression such as glycated albumin (fructosamine, the canine equivalent of human HbA1c) and c-peptide were addressed. Results: Significant differences in adaptive immune lymphocytes, innate immune macrophages/monocytes and neutrophils and differences in platelets were detected between CDM and HC based on CBC. Significant differences in serum glucose, cholesterol and the liver function enzyme alkaline phosphatase were also detected. A systemic immune inflammation index (SII) and chronic inflammation index (CII) as measures of dynamic changes in adaptive and innate cells between inflammatory and non-inflammatory conditions were created with highly significant differences between CDM and HC. Th40 cells (CD4+CD40+ T cells) that are demonstrably pathogenic in mouse T1DM and able to differentiate diabetic from non-diabetic subjects in human T1DM were significantly expanded in peripheral blood mononuclear cells. Conclusions: Based on each clinical finding, CDM can be categorized as an autoimmune condition. The association of significantly elevated Th40 cells in CDM when compared to HC or to osteoarthritis, a chronic but non-autoimmune disease, suggests peripheral blood Th40 cell numbers as a biomarker that reflects CDM chronic inflammation. The differences in SII and CII further underscore those findings.

Indexed as

Autoimmune DiseasesDiabetes Mellitus, Type 1AnimalsBiomarkersCD4-Positive T-LymphocytesDogsHospitals, AnimalHospitals, TeachingHumansInflammationLeukocytes, MononuclearMiceBiomarkersautoimmunecanine diabetes mellituschronic inflammationinflammatory indexTh40 cells

Identifiers

PMID38318506
PMCPMC10839093
OpenAlexW4391108352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.